BridgeRNAton: Scandalously Precise DNA Matchmaking by Non-Coding RNAs

In research from the Arc Institute highlighted by a recent article in Science, RNA takes charge — reweaving the genome instead of cutting it apart.

Has DNA been retired? After a long-standing career as the genomic blueprint, DNA might be handing over its role of molecular matchmaker to RNA. The discovery of a new genomic rearrangement system has revealed that RNA not only transcribes and regulates but can also rebuild the genome itself.

When Nicholas Perry and colleagues at the Arc Institute introduced ISCro4 as their diamond of the season, it wasn’t merely another genome editing system but rather the much-anticipated sequel to the CRISPR editing chapter. This RNA-guided platform does not just tweak single genes; it rearranges whole genomic neighborhoods by shuffling, flipping, deleting, and/or re-stitching million-base-pair segments of DNA with great finesse. ¹

Pulling the strings behind the scenes is Bridge RNA. As first described by Matthew Durrant, Perry, and colleagues last year, Bridge RNAs represent a new class of bispecific guide RNAs capable of guiding DNA rearrangements in a way that is similar to, though conceptually distinct from, CRISPR-Cas systems. ² Unlike CRISPR-Cas systems, which guide cleavage of a single nucleic acid target, Bridge RNAs connect rather than cut, bringing donor and template DNA close enough for the recruited recombinase to carry out the programmed insertion, deletion, or inversion with remarkable precision, provided that all four components — Bridge RNA, recombinase, donor DNA, and target DNA — are present. ³

Each Bridge RNA is a molecular multitasker, with its two internal loops doing the heavy lifting: one base-pairing with the target site in the host genome, the other binding the donor sequence within the transposon itself. This dual recognition quite literally bridges the two DNA molecules, bringing them together for precise rearrangements.^2,3

Of humble origins, these non-coding RNAs are produced by IS110 transposons, a family of minimal, autonomous, cut-and-paste bacterial mobile genetic elements that naturally excise and reinsert themselves at a different genomic location. When excised, these “jumping genes” form circular intermediates that transcribe highly structured RNAs which bind their encoded recombinase, assembling a ribonucleoprotein complex that orchestrates site-specific DNA recombination.^4,5

The choreography of top-strand cleavage, strand exchange, and junction resolution was captured in cryo-electron microscopy snapshots by Hiraizumi et al. ³ The structures reveal a dynamic, precise, and balanced RNA-guided molecular dance: the recombinase active site spans two dimers, synchronizing operations across donor and target DNA, and reinforcing the dependence of the modular programmability of the system on steric and geometric constraints.^3,6 These polaroids expand our understanding of what RNA-guided systems can do beyond the familiar nucleolytic editing of CRISPR–Cas enzymes, giving us a glimpse into the next generation of programmable genome editing technology, providing insight into the architecture of this system, which was previously only inferred from biochemical data (Fig. 1).^2,3,7

OPEN IN VIEWER

FIG. 1.

Bridge RNA structure, components, and editing mechanism. (a) Schematic representation of the structure and circularisation of an IS110 element highlighting the core sequences that can be engineered to drive the editing (left); schematic representation of Bridge RNA highlighting the double loop bispecific structure (b) The recombinase binds donor and target DNA. (c) RuvC-Tnp cleavage, Holliday Junction formation and resolution. (d) Recombined DNA strands showing inserted donor DNA between target DNA portions. Adapted from Perry et al., Barbas et al. and Li et al.^1,6,8

Compact — coming in at ∼150–250 nucleotides of RNA and ∼300–460 amino-acids of recombinase—self-sufficient, and reprogrammable, this system is a minimalist genome editing platform that is potentially easier to deliver than bulkier CRISPR-Cas nucleases.^2,3 Both the target and donor-binding loops can be independently engineered to detect specific sequences and direct the DNA edits with high fidelity and low mismatch tolerance.^3,8 The diversity among IS110 and IS111 transposons adds to the design space, offering a natural library of interchangeable RNA parts for synthetic biology and therapeutic applications. Where CRISPR exploits endonucleolytic cleavage, ISCro4 recombines, introducing a gentler and more precise route of guided recombination, which could lay the basis for a third generation of RNA-guided genome engineering tools beyond the CRISPR-based paradigm.^4,6

Building Bridges

In the recent Science report, Perry et al. built on their 2024 studies by taking the Bridge RNA concept from a biochemical curiosity to a megabase-scale genome editing platform.

The authors outlined a modular workflow for programming new Bridge RNAs derived from ISCro4 and related recombinases, contextually showing how these can, in mammalian systems, direct rearrangements that span hundreds of kilobases while also enhancing their efficiency and specificity.^1–3

While earlier studies had established the molecular mechanism,^2,3 the most recent publication demonstrated that this can be harnessed for large-scale genomic rearrangements in human cells.^1–3  The Science study effectively moves the system from mechanistic proof-of-concept to functional genome rewriting, marking a practical expansion of the Bridge RNA paradigm with implications for disease modelling and correction.

Indeed, this is the first time we have seen RNA guide recombination rather than merely direct DNA cutting or fixed-site rearrangements.^2,3 Before Bridge RNA, there was no compact RNA-guided system capable of orchestrating DNA exchanges between arbitrary genomic sites — a conceptual leap beyond CRISPR’s cut-and-repair model.^7,9 With efficiencies rivalling and even surpassing those of older editing tools, ISCro4 provides a new way to study gene interaction and misbehavior in genetic diseases, holding promise for modelling large chromosomal rearrangements observed in various cancers and for correcting conditions like Friedreich’s ataxia.^1,8

Yet, for clinical applications, several challenges remain. While the system performs robustly in vitro, achieving coordinated tissue-specific delivery of all components will be crucial for therapeutic success.^7,8 Specificity and safety also demand rigorous testing, with essential comprehensive off-target analysis to confirm that recombination occurs exclusively at intended sites.^1,3 And as genome engineering shifts from cutting DNA to rearranging it, oversight and policy will need to adapt to address this new paradigm of large-scale genomic rewriting. Beyond technical refinement, regulatory and ethical frameworks must evolve in parallel to bring forward a comprehensive checklist for clinical applications.^4,10

If these challenges can be overcome, the implications are profound. The ability to reconfigure megabase-sized regions of the genome could enable correction of structural variants, removal of pathogenic repeats, and restoration of disrupted regulatory landscapes.^1,3 Unlike single-site editing, programmable recombination offers a means to restore genomic architecture itself, potentially transforming how complex genetic disorders and chromosomal rearrangements are approached.

For decades, DNA has been the blueprint and RNA the messenger. CRISPR blurred that boundary by letting RNA direct the genetic scissors. Bridge RNAs now completely dissolve that paradigm. RNA is no longer relegated to transcribing, regulating, or reading DNA; it is rebuilding it. What started off as a bacterial survival mechanism, now represents a significant breakthrough in our ability to manipulate DNA with precision and scope. ¹¹

While still in the research phase, RNA-guided recombination technologies such as Bridge RNA hold great promise for rewriting not only the genome’s sequence but also its structure and perhaps its future.